Exclusive Summary

• Capitalize on the upcoming $2 billion patent cliff: With the originator's core patents expiring from 2025 onwards, securing a distribution agreement now guarantees a lucrative first-to-launch or early-mover generic advantage globally.
• A high-value, underserved rare disease market: As the next-generation, guideline-recommended first-line therapy with lower hepatotoxicity, Macitentan captures the stable, massive lifelong demand of Pulmonary Arterial Hypertension (PAH) patients.
• Accelerated market entry with robust regulatory compliance: Fully supported by internationally standardized GMP manufacturing and comprehensive English CTD dossiers, empowering fast-track regulatory approvals for overseas clients.
• Disruptive cost-efficiency for premium margins: Leveraging China's end-to-end API-to-FDF integrated supply chain, our product dramatically reduces the exorbitant originator therapy costs, offering distributors aggressive bidding elasticity and exceptional profit margins.